The EMJ Podcast | Episode 215
Shaping the field of cardiovascular medicine, emerging technologies have the potential to transform the treatment of cardiovascular disease. Explore the latest advancements in cardiology with Jonathan and Nicholas Leeper, Professor of Surgery, Chief of Vascular Medicine, and Director of Vascular Research at Stanford University, California, USA.
Spotify | Apple | Amazon Music | Download MP3 (40:09 mins)
Nicholas Leeper is a Professor of Surgery, Chief of Vascular Medicine, and Director of Vascular Research at Stanford University, California, USA.
Earning a B.A. in Chemistry and an M.D. from the University of Chicago, Leeper then completed his internal medicine training at the University of California, San Francisco, USA, before pursuing fellowships in cardiovascular disease and vascular medicine at Stanford University.
He now leads a translational laboratory focused on leveraging human genetics and advanced immunology approaches to discover new cardiovascular therapeutics. He is also a co-founder of two biotechnology companies, Forty Seven, Inc. and Bitterroot Bio, which aim to prevent cancer and cardiovascular disease, the world’s two leading killers. Leeper has produced an impressive collection of peer-reviewed publications and is actively engaged with the Society for Vascular Medicine (SVM), the Gordon Research Conferences (GRC), and the American Society for Clinical Investigation (ACSI).
- 00:00 – Introduction
- 02:37 – Nicholas’s journey into cardiovascular medicine
- 04:40 – Exciting advancements in cardiovascular research
- 07:41 – Impact of COVID-19 on clinical practice and the fear of predatory journals
- 12:13 – ‘Bench-to-bedside’ approach
- 15:50 – Bitterroot Bio and Forty Seven Inc.
- 22:53 – Initiatives Nicholas is involved in that are aiding cardiovascular care
- 27:22 – The future of cardiovascular medicine
- 30:45 – Biological similarity between cancer and cardiovascular disease
- 34:42 – Nicholas’s three magic wishes
